OncoMatch/Clinical Trials/NCT05862285
A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study
Is NCT05862285 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments for cancer.
Treatment: Ipatasertib · Tiragolumab · Atezolizumab · Tiragolumab and Atezolizumab · Bevacizumab · Entrectinib · Inavolisib · Divarasib — The purpose of this extension study is to provide continued treatment with Roche investigational medicinal product (IMP\[s\]) monotherapy or Roche IMP(s) combined with other agent(s) or comparator agent(s) for eligible participants with cancer who are still on study treatment at the time of roll-over from the parent study and who do not have access to the study treatment locally.
Check if I qualifyExtracted eligibility criteria
Prior therapy
Must have received: Roche IMP-based therapy or comparator agent in a Genentech- or Roche-sponsored study — parent study
Eligible for continuing Roche IMP-based therapy at the time of roll-over from the parent study, as per the parent study protocol OR Eligible for continuing the comparator agent(s) in a Genentech- or Roche-sponsored study as per the parent study protocol, with no access to commercially available comparator agent
Cannot have received: any anti-cancer treatment (other than treatment permitted in the parent study)
Treatment with any anti-cancer treatment (other than treatment permitted in the parent study) during the time between last treatment in the parent study and the first dose of study treatment in this extension study
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify